Lipoproteins and the Development of Restenosis After Stent Implantation in the Superficial Femoral Artery in Patients with Peripheral Artery Disease

[1] Sniderman AD(2003)Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 777-780

[2] Furberg CD(2007)European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 2375-2414

[3] Keech A(2006)Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study J Intern Med 259 259-266

[4] Graham I(2001)High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2026-2033

[5] Atar D(2004)Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy J Intern Med 255 188-205

[6] Borch-Johnsen K(2007)Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study Arterioscler Thromb Vasc Biol 27 661-670

[7] Walldius G(2002)Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients Diabet Med 19 300-306

[8] Aastveit AH(2009)Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty J Endovasc Ther 16 389-396

[9] Jungner I(2006)Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty Eur J Vasc Endovasc Surg 31 59-63

[10] Walldius G(1991)Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis Kidney Int 39 754-760

[1] Sniderman AD(2003)Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 777-780

[2] Furberg CD(2007)European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 2375-2414

[3] Keech A(2006)Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study J Intern Med 259 259-266

[4] Graham I(2001)High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2026-2033

[5] Atar D(2004)Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy J Intern Med 255 188-205

[6] Borch-Johnsen K(2007)Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study Arterioscler Thromb Vasc Biol 27 661-670

[7] Walldius G(2002)Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients Diabet Med 19 300-306

[8] Aastveit AH(2009)Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty J Endovasc Ther 16 389-396

[9] Jungner I(2006)Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty Eur J Vasc Endovasc Surg 31 59-63

[10] Walldius G(1991)Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis Kidney Int 39 754-760